LENALIDOMIDE: RECENT ARMAMENTARIUM IN MANAGEMENT OF MULTIPLE MYELOMA

  • Ajay K Gupta Armed Forces Medical College
  • Ashok Kumar Sharma Armed Forces Medical College
  • Anjan Khadka Armed Forces Medical College
  • Navdeep Dahiya Armed Forces Medical College
  • Dick BS Brashier Armed Forces Medical College
  • Sushil K Sharma Armed Forces Medical College

Abstract

Lenalidomide is an analogue of thalidomide. It is an oral immunomodulatory compound with potent activity and different toxicity profile than thalidomide. Lenalidomide is one of the novel drug agents used to treat multiple myeloma. Multiple myeloma (MM) is a B cell malignancy characterized by excess monotypic plasma cells in the bone marrow. Lenalidomide in combination with dexamethasone is one of the most promising MM novel treatment options. It induces at least additive direct cytotoxicity in multiple myeloma cells. The lenalidomide has possibility of being used as an adjuvant in support of more specific immunotherapeutic interventions including cancer chemotherapy, anticancer vaccines and adoptively transferred cells which warrants further investigation.

Downloads

Download data is not yet available.

Author Biographies

Ajay K Gupta, Armed Forces Medical College
Pharmacology
Ashok Kumar Sharma, Armed Forces Medical College
Pharmacology
Anjan Khadka, Armed Forces Medical College
Pharmacology
Navdeep Dahiya, Armed Forces Medical College
Pharmacology
Dick BS Brashier, Armed Forces Medical College
Pharmaoclogy
Sushil K Sharma, Armed Forces Medical College
Pharmacology
Statistics
147 Views | 185 Downloads
How to Cite
1.
Gupta A, Sharma A, Khadka A, Dahiya N, Brashier D, Sharma S. LENALIDOMIDE: RECENT ARMAMENTARIUM IN MANAGEMENT OF MULTIPLE MYELOMA. JDDT [Internet]. 15May2014 [cited 16Jan.2021];4(3):87-0. Available from: http://jddtonline.info/index.php/jddt/article/view/819